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Summary
The hematopoietic system develops during embryo-
genesis at temporally and anatomically restricted
sites. The anatomical origin of definitive HSCs is not
fully resolved, and little is known about how the dif-
ferent fetal hematopoietic microenvironments direct
HSC development. Here, we show that the mouse pla-
centa functions as a hematopoietic organ that har-
bors a large pool of pluripotent HSCs during midge-
station. The onset of HSC activity in the placenta
parallels that of the AGM (aorta-gonad-mesonephros)
region starting at E10.5–E11.0. However, the placental
HSC pool expands until E12.5–E13.5 and contains
>15-fold more HSCs than the AGM. The expansion of
the CD34+c-kit+ HSC pool in the placenta occurs prior
to and during the initial expansion of HSCs in the fetal
liver. Importantly, the placental HSC pool is not ex-
plained by rare circulating HSCs, which appear later.
These data support an important, but unappreciated,
role for the placenta in establishing the mammalian
definitive hematopoietic system.
Introduction
Blood cell production is sustained throughout the life-
time of an individual by hematopoietic stem cells
(HSCs). HSCs are defined by their ability to engraft
bone marrow (BM) of irradiated hosts, self-renew, and
differentiate into all types of mature blood cells (Akashi
and Weissman, 2001). During postnatal life, the bone
marrow supports both self-renewal and differentiation
of HSCs in specialized microenvironmental niches (Arai
et al., 2004; Avecilla et al., 2004; Calvi et al., 2003; Nils-
son et al., 2001; Tokoyoda et al., 2004; Zhang et al.,
2003a), whereas embryonic hematopoiesis is compart-
mentalized into anatomical sites where specific stages
of hematopoietic development and different lineage
outputs are manifest.*Correspondence: stuart_orkin@dfci.harvard.edu
4 Present address: Hematopoietic Stem Cell Laboratory, Lund Stra-
tegic Research Center for Stem Cell Biology and Cell Therapy, Lund
University, 221 84 Lund, Sweden.The hematopoietic system originates from the meso-
dermal germ layer, which gives rise to the hemangio-
blast, a bipotential precursor for blood and endothe-
lium (Choi et al., 1998; Huber et al., 2004; Sabin, 1920).
In murine embryos, commitment to the hematopoietic
lineage is evident at embryonic days (E) 7.0–7.5 in the
yolk sac, which first produces a transient population of
primitive erythrocytes that express embryonic globins
(Palis et al., 1999). Shortly thereafter, the yolk sac gives
rise to a second wave of progenitors that consists of
single- and multilineage myeloerythroid progenitor cells.
However, the yolk sac microenvironment does not sup-
port differentiation of definitive progenitors, which
instead exit via the vitelline veins to the fetal liver rudi-
ment, where definitive erythroid differentiation is initi-
ated. Paradoxically, HSCs, defined by the ability to re-
constitute adult bone marrow hematopoiesis, are not
yet found in these hematopoietic tissues, although em-
bryonic blood cell production has been ongoing forw3
days. The first definitive HSCs appear after E10.5 in low
numbers in the AGM (aorta-gonad-mesonephros) re-
gion in the embryo proper and in the vitelline and umbil-
ical arteries that connect the dorsal aorta with the yolk
sac and the placenta, respectively (Cumano et al.,
1996; de Bruijn et al., 2000; Godin et al., 1999; Medvin-
sky and Dzierzak, 1996; Muller et al., 1994). The AGM
region develops from the para-aortic splanchnopleura
and represents another independent site for de novo
hematopoiesis. As HSCs in the AGM region are only
found for a short time, and the number of HSCs and
progenitors is low at all times, the AGM is not consid-
ered to function as a major site for expansion or differ-
entiation of HSCs. Instead, accumulation of HSCs is
seen shortly thereafter in the fetal liver, which also
serves as the main site for hematopoietic differentiation
during fetal life (Ema and Nakauchi, 2000) until hemato-
poiesis shifts to the bone marrow around birth. As no
de novo formation of HSCs occurs in the fetal liver, my-
eloerythroid progenitors and HSCs from the yolk sac
and the AGM region have been assumed to be respon-
sible for fetal liver seeding (Houssaint, 1981; Johnson
and Moore, 1975). However, the exceedingly rapid ex-
pansion of the fetal liver HSC pool, taken together with
the length of the cell cycle, has raised the question of
whether the few HSCs from the AGM region alone can
account for the expansion of the fetal liver HSC pool,
or whether the yolk sac, or yet another site, also con-
tributes to this process (Kumaravelu et al., 2002) by
supporting the genesis, maturation, or expansion of
adult-type HSCs. Notably, as early as E9, the yolk sac
contains immature HSCs, or pre-HSCs, that are capa-
ble of reconstitution of the hematopoietic system of
newborn recipient mice (Yoder et al., 1997a; Yoder et
al., 1997b). Whether these cells contribute to the adult,
definitive hematopoietic system during normal devel-
opment is unknown.
In avian embryos, de novo hematopoiesis occurs in
an additional mesodermal appendage, the allantois
(Caprioli et al., 1998; Caprioli et al., 2001). In mice, the
allantois forms the umbilical cord and the mesodermal
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366components of the fetal placenta upon fusion with the A
fchorion. The allantois develops from the epiblast during
gastrulation and grows into the exocoelomic cavity as a a
bmesodermal extension of the posterior primitive streak.
The allantois fuses with the chorion at E8–E8.5 and R
Tforms a complex vascular network called the placental
labyrinth, which consists of endothelial cell-lined fetal e
acapillaries and trophoblast-lined maternal blood si-
nuses, and permits the exchange of gases and nutri- e
hents between maternal and fetal circulatory systems
(Adamson et al., 2002; Downs, 2002; Downs and Gard- w
sner, 1995; Rossant and Cross, 2001). The placenta has
not been recognized as a hematopoietic organ, al- c
pthough Melchers reported the presence of fetal B cell
precursors in murine placenta 25 years ago by using l
tcoculture on rat thymic filler cells and plaque-forming
cell assays (Melchers, 1979). Since these early studies, r
Tplacental hematopoiesis has not been reassessed until
Alvarez-Silva et al. showed by in vitro clonogenic as- t
ssays that the placenta is a rich source for multipotential
hematopoietic progenitors before they colonize the fe- a
btal liver. The results of these assays suggest that the
placenta may function as a hematopoietic organ during
development (Alvarez-Silva et al., 2003). However, hema- P
topoietic progenitors in the mouse embryo form prior to o
and independently of HSCs that establish the definitive T
hematopoietic system. We therefore asked whether the f
placenta also supports the development of true HSCs C
that have the ability to self-renew and permanently re- a




sWe performed a spatial and temporal analysis of HSC
activity during mouse embryonic development by using a
tthe long-term transplantation assay, which is the most
stringent and reliable assay for HSCs. In this study, we c
balso assessed HSC activity in the placenta, which has
not been recognized as an organ that participates in c
HHSC development. Collagenase-treated hematopoietic
organs from E10.5–E18.5 conceptuses were trans- d
1planted in limiting dilutions, quantified as embryo equiva-
lents (ee), into congenic, irradiated adult recipients to- b
(gether with competitor bone marrow cells (Table 1).
Hematopoietic reconstitution by fetus-derived CD45.1/ 2
tCD45.2 cells was analyzed by flow cytometry, and
HSCs were quantified as repopulating units (RUs/ee). a
DThe Onset of HSC Activity in the Placenta
Rare hematopoietic cells (0.1 RUs/ee) capable of con- a
Ttributing to peripheral blood of irradiated adult recipi-
ents over 10–12 weeks were found in the placenta al- y
kready at E10.5 (33–36 sp, somite pairs). The temporal
emergence of these hematopoietic cells was similar to H
twhat was seen in the caudal half of the embryo and the
yolk sac (Figure 1A; Table 2). However, RUs in the entire e
fconceptus were rare at this stage (0.3 RUs) and gave
rise to very low (<1%–2%) hematopoietic reconstitution s
tthat frequently was lost over time. At E11.0 (37–40 sp),
the conceptus contained, on average, one long-term e
prepopulating unit (0.48 LT-RUs in placenta, Figure 1B;
Table 2), and the first HSCs yielding a higher (>10%) t
tlevel of hematopoietic reconstitution were seen in theGM region and the placenta. No LT-RUs were yet
ound in the fetal liver rudiment or in circulating blood,
lthough clonogenic progenitors were abundant (see
elow). By E11.5 (41–45 sp), the total number of LT-
Us in the conceptus had increased tow11 (Figure 1C;
able 2). Consistent with previous studies (Kumaravelu
t al., 2002), LT-HSCs were also found in the fetal liver
nd the yolk sac at this stage, and HSCs were fairly
venly distributed between the placenta and the known
ematopoietic organs. The increase of HSC numbers
as accompanied by a concomitant increase in recon-
titution potential of fetal HSCs. The first engrafting
ells also appeared in fetal blood, although the com-
etitive reconstitution potential of circulating cells was
ow (<1%) (Figure 1C; Table 2). These results show that
he placenta represents yet another site at which adult
econstituting HSCs reside during mouse development.
he onset of HSC activity in the placenta coincides with
hat in the AGM and the yolk sac, and it precedes HSC
eeding of the fetal liver. Importantly, placental HSCs
ppear before HSCs can be detected in circulating
lood.
luripotency and Self-Renewal Ability
f Placental HSCs
he multilineage potential of placental HSCs was veri-
ied by demonstrating the presence of fetus-derived
D45.1/CD45.2+ myeloid (Gr1/Mac1), B lymphoid (B220),
nd T-lymphoid progeny (CD4/CD8) in the peripheral
lood of the recipient animals (Figure 2A). At E10.5,
-lymphoid lineage could not be confirmed for any fetal
rgans due to the low level of hematopoietic engraft-
ent, whereas, from E11.0 onward, placental HSCs,
imilar to the HSCs derived from the AGM region, were
ble to give rise to multilineage long-term reconstitu-
ion for >5–10 months. Likewise, engraftment of pla-
enta-derived hematopoietic cells had occurred in the
one marrow (Figure 2B), thymus, and spleen of the re-
ipient animals (data not shown). Furthermore, placental
SCs were able to self-renew in the recipient animals, as
emonstrated by secondary transplantation of 1:10 and
:100 fractions of BM from primary recipients that had
een transplanted with placenta (0.3–1 ee) and AGM-
1–3 ee) derived cells from E11.5 conceptuses (Figures
B and 2C). These results show that HSCs located in
he placenta possess functional properties of bona fide
dult BM reconstituting hematopoietic stem cells.
evelopmental Kinetics of Placental HSCs
nd Progenitors
o assess hematopoietic activity in the placenta be-
ond the time period when HSCs are generated in
nown hematopoietic sites, we defined the kinetics of
SCs and progenitors throughout mid- and late gesta-
ion. Remarkably, between E11.5 and E12.5, a marked
xpansion of HSCs occurred in the placenta and the
etal liver (20- and 28-fold, respectively), whereas no
ignificant increase of the HSC pool was observed in
he AGM region or the yolk sac (Figure 3A). Hematopoi-
tic expansion in the placenta favored HSCs more than
rogenitors, as the clonogenic myeloerythroid progeni-
or pool in the placenta increased only 2-fold during
his period (Figure 3B). The competitive repopulation
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367Table 1. Donor Fetal Hematopoietic Organs
Recipient Doses Transplanted
Day of Gestation Fetal Organ Cells/ee (10e3) ± SEM Mice (n) (ee) Exp (n)
E9.5 (23–25 spa) Placenta 130 ± 30 ND ND 2
Yolk sac 128 ± 20 ND ND 2
Caudal half 181 ± 79 ND ND 2
Decidua 532 ND ND 1
E10.5 (33–36 sp) Placenta 267 ± 66 33 3 5
Yolk sac 134 ± 14 31 3 5
Caudal half 245 ± 99 36 3 5
Blood 116 ± 37 29 3 5
Decidua 158 ± 29 5 3 2
Rostral half 99 ± 5 8 3 2
E11.0 (37–40 sp) Placenta 236 ± 28 27 0.3, 1 4
Yolk sac 212 ± 22 22 0.3, 1, 3 4
AGM 90 ± 15 22 0.3, 1, 3 4
Caudal half (w/o AGM) 117 4 1 1
Fetal liver 51 ± 3 19 0.3, 1, 3 4
Blood 368 ± 146 18 0.3, 1, 9 4
Cord 60 5 1 1
Decidua 118 7 1 1
E11.5 (41–45 sp) Placenta 458 ± 43 25 0.3, 1 3
Yolk sac 293 ± 112 20 0.3, 1 3
AGM 223 ± 74 19 0.3, 1 3
Fetal liver 241 ± 91 15 0.3, 1 3
Blood 182 ± 87 17 0.3, 1 3
Cord ND 5 1 1
E12.5 Placenta 1,528 ± 497 33 0.01, 0.1, 0.3 3
Yolk sac 532 ± 122 15 0.1, 0.3 3
AGM 368 ± 126 15 0.1, 0.3 3
Fetal liver 1,254 ± 626 25 0.001, 0.01 3
Blood 1,817 ± 403 21 0.3, 1 3
Cord ND 4 1 1
Decidua 195 8 0.3 1
E13.5 Placenta 1,323 ± 576 39 0.01, 0.1 3
Yolk sac 747 ± 396 24 0.01, 0.1 3
AGM 365 ± 5 15 0.1, 0.3 3
Fetal liver 4,192 ± 356 20 0.001 3
Blood 1,624 ± 557 34 0.01, 0.1 3
Decidua 260 ± 217 5 1 2
E15.5 Placenta 1,238 ± 210 26 0.3 4
Yolk sac 558 ± 106 26 0.3 4
Fetal liver 24,188 ± 2,314 12 0.001, 0.01, 0.1 4
Blood 729 ± 173 30 0.1, 0.3 4
Bone marrow 129 ± 67 12 1 2
E18.5 Placenta 1,842 ± 622 17 0.1, 0.3 3
Yolk sac 1,442 ± 485 14 0.1, 0.3 3
Fetal liver 242,515 ± 60,761 11 0.001, 0.01 3
Blood 191 ± 81 20 0.1, 0.3 3
Bone marrow 420 ± 232 14 0.1, 0.3 3
a sp, somite pairs.ability of placental HSCs at this stage was high, result-
ing in sustained multilineage reconstitution that often
increased over time, whereas fetal liver HSCs, although
almost 2-fold higher in numbers at E12.5 (50 in the pla-
centa and 93 in the fetal liver), were more hetero-
geneous in reconstitution potential early on, as shown
by lower competitive repopulation ability of fetal liver
HSCs at E12.5 (Table 2). At E13.5, the average competi-
tive repopulation level of HSCs in the fetal liver was
similar to placental HSCs (data not shown).
The size of the placental HSC pool was maintained
through E13.5, but it diminished >10-fold by E15.5,
while the HSC pool in the fetal liver continued to ex-
pand (Figure 3A). From E12.5 onward, a gradual increase
of LT-RUs in fetal circulation occurred, exceeding innumbers those in the placenta by E15.5. Bone marrow
seeding by clonogenic progenitors and rare cells that
gave rise to transient in vivo reconstitution was evident
at E15.5, whereas long-term reconstituting HSCs ap-
peared in the BM by the end of gestation (Figure 3A).
In summary, the developmental kinetics of HSCs and
progenitors in the placenta is unique and does not re-
flect hematopoietic activity in any other fetal hemato-
poietic organ or in circulating blood.
Surface Phenotype of Placental HSCs
and Progenitors
The immunophenotype of placental HSCs and progeni-
tors was defined by assaying subpopulations of cells
that had been sorted based on CD34 and c-kit expres-
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(A–C) Reconstitution potential of fetal hematopoietic organs at (A) E10.5 (33–36 sp), (B) E11.0 (37–40 sp), and (C) E11.5 (41–45 sp). Symbols
represent the competitive repopulation level of fetal CD45.1/CD45.2 cells, in logarithmic scale, at 10–12 weeks after transplantation, in
individual recipient mice transplanted with the indicated embryo equivalents of each hematopoietic tissue.sion. An equal dose in embryo equivalents of each p
4sorted subpopulation (R1–R4, Figure 4A) was trans-
planted in order to determine which subpopulation con- (
ptained placental HSCs. All HSC/RUs in E12.5 placentas
were found within the c-kithiCD34+ population, which w
tcomprises up to 1%–2% of nucleated cells obtained
from collagenase-treated placentas (Figures 4A and w
c4C). Likewise, most fetal liver HSCs were c-kithiCD34+
(Figures 4B and 4C). The majority (87%) of CFU-Cs in t
Rthe placenta were also c-kit+CD34+, although some
(13%) were found among c-kit+CD34− cells (Figure 4D). t
cThe proportions of c-kithiCD34+ and c-kithiCD34− pop-
ulations in the placenta contrast with the fetal liver, t
twhere the c-kithiCD34− population was abundant, re-
flecting ongoing definitive erythropoiesis. Accompany- d
ling definitive erythropoiesis in midgestation fetal liver
was further shown by the abundance of CFU-Es and f
pCD71hiter119− proerythroblasts (Zhang et al., 2003b),
while these erythroid precursors were infrequent in the p
gplacenta (data not shown). These results suggest that
the placenta provides a site of residence for c-kithi a





oMidgestation Mouse Placenta Is a Previously
Unrecognized Site of Residence for HSCs r
tWe have reassessed the anatomical distribution of fetal
hematopoietic stem cells and identified a previously c
runrecognized, to our knowledge, HSC niche in the mu-
rine conceptus. Our data show that, during midgesta- i
ation, the mouse placenta harbors a large pool of HSCs
that possess functional properties of true adult-type h
tHSCs, i.e., the potential to provide high-level, long-
term, multilineage reconstitution and to self-renew upon m
rserial transplantation. The magnitude of HSC activity
in the placenta is striking, as the placental HSC pool v
texceeds in numbers those in all other fetal hematopoi-
etic organs other than the fetal liver. HSC activity, as s
Hdefined by adult BM reconstitution ability, in the mouselacenta starts at E10.5–E11.0, which corresponds to
–5 weeks of gestational age in the human embryo
Rugh, 1994). The onset of HSC activity in the placenta
arallels that of the AGM region. HSC activity begins
ith the appearance of rare hematopoietic precursors
hat give rise to low-level, often transient reconstitution,
hereas, by E11.5, hematopoietic reconstitution be-
omes robust. In contrast to the AGM and the yolk sac,
he HSC pool in the placenta expands to w50 HSC/
Us at E12.5–E13.5 and declines again during the third
rimester. Thus, the kinetics of HSC activity in the pla-
enta is unique and does not mimic hematopoietic ac-
ivity in any other hematopoietic organ. Interestingly,
he temporal kinetics of HSC activity in the placenta as
efined by the long-term transplantation assay paral-
els that of B cell potential, as assessed by plaque-
orming capacity (Melchers, 1979). In that study, B cell
otential in the placenta was evident as early as E9.5,
eaked at E12.5, and declined again toward the end of
estation, whereas B cell precursors in the fetal liver
ppeared later.
natomical Origin of Placental HSCs: Allantoic
esoderm as a Putative Source for HSCs
he experimental approach used in this study allows
he quantitation of the HSC pool that resides in each
rgan at each time point of analysis, but does neither
eveal the origin of the HSCs nor their ultimate destina-
ion. However, the early appearance of HSCs in the pla-
enta suggests that the allantoic mesoderm and its de-
ivatives (the umbilical cord and the placenta) may be
nvolved in HSC generation and/or maturation into
dult-type HSCs (Figure 5). Indeed, previous studies
ave documented the formation of hematopoietic clus-
ers and definitive HSCs in the umbilical artery; the for-
ation of these clusters and HSCs coincides tempo-
ally with HSC generation in the dorsal aorta and the
itelline artery (de Bruijn et al., 2000). HSC activity in
he umbilical cord was also assessed in this study in
ome experiments, demonstrating the presence of
SCs in the cord, albeit at lower numbers than in the
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369placenta (Table 2). Whether de novo hemogenic activity
extends into the placenta remains to be studied.
Previous studies have suggested that the allantoic
vasculature forms de novo by vasculogenesis rather
than by angiogenic sprouting of the intraembryonic
vasculature. Allantoic vasculogenesis is initiated at the
distal tip of the allantois that contains the oldest meso-
derm, and it progresses in two directions, distally to
fuse with the chorion and to form the placenta laby-
rinth, and proximally to connect with the dorsal aorta
(Downs et al., 2004). Grafting experiments that used
genetically marked allantoises implicate similar devel-
opmental potential for allantoic and lateral plate meso-
derm, as mesoderm from the distal and proximal re-
gions of the allantois was capable of forming not only
vasculature in the placenta and the umbilical cord, but
also endothelium and underlying mesenchyme of the
dorsal aorta, a site at which AGM HSCs are formed
(Downs and Harmann, 1997). In contrast, allantoic
mesoderm did not contribute to paraxial (presomitic)
mesoderm. Thus, it is likely that allantoic mesoderm
gives rise to HSCs in the umbilical artery and possiblyTable 2. The Onset of HSC Activity in the Mouse Embryo
Time
Posttransplantation 3–4 Weeks 10–12 Weeks >5 Months
ER >5
Mean Months/ER Mean
ERa/ ST-RUs/ Mean Rec.b ± LT-RUs/ Rec. ± SD at 10–12 Rec. ± SD
Day of Gestation Organ Total ee SD (%) ER/Total ee (%) Weeksc (%)
E10.5 (33–36 spd) Placenta 5/33 0.096 0.32 ± 0.35 6/33 0.103 0.39 ± 0.43 3/4 0.18 ± 0.16
Yolk sac 13/31 0.157 0.96 ± 1.57 8/31 0.107 0.45 ± 0.66 2/6 0.17 ± 0.07
Caudal half 10/36 0.125 1.85 ± 4.07 9/36 0.107 1.05 ± 2.04 4/7 0.31 ± 0.11
Blood 0/29 0 N/A 0/29 0 N/A N/A N/A
Decidua 0/5 0 N/A 0/5 0 N/A N/A N/A
Rostral half 0/8 0 N/A 0/8 0 N/A N/A N/A
Total 0.378 0.317
E11.0 (37–40 sp) Placenta 14/27 0.733 2.8 ± 5.8 8/27 0.477 2.2 ± 3.5 7/8 2.5 ± 5.9
Yolk sac 12/22 0.422 0.5 ± 0.7 7/22 0.133 0.2 ± 0.2 4/4 0.1 ± 0.07
AGM 7/22 0.274 18.5 ± 21.5 9/22 0.306 20.7 ± 29.0 5/9 42.2 ± 35.0
Caudal half 0/4 0 N/A 0/4 0 N/A N/A N/A
(w/o AGM)
Fetal liver 1/19 0.042 0.10 0/19 0 N/A N/A N/A
Blood 3/18 0.1 0.14 ± 0.10 0/18 0 N/A N/A N/A
Cord 0/5 0 N/A 0/5 0 N/A N/A N/A
Decidua 0/7 0 N/A 0/7 0 N/A N/A N/A
Total 1.571 0.966
E11.5 (41–45 sp) Placenta 20/25 2.5 25.9 ± 22.4 18/23 2.5 29.7 ± 35.8 12/12 28.9 ± 41.9
Yolk sac 19/20 2.1 20.9 ± 27.0 19/20 2.1 28.7 ± 39.8 13/16 21.4 ± 35.7
AGM 16/19 2.3 26.5 ± 26.0 15/19 2.0 50.1 ± 41.5 13/14 48.0 ± 43.6
Fetal liver 15/15 3.3 20.3 ± 23.5 15/15 3.3 21.6 ± 32.4 11/13 12.7 ± 26.2
Blood 8/17 1.8 1.8 ± 1.2 5/14 0.6 0.6 ± 0.3 3/5 1.8 ± 1.7
Cord 1/5 0.2 26.2 1/5 0.2 84.6 1/1 92.6
Total 11.4 10.9
E12.5 Placenta 22/33 42.8 52.9 ± 36.0 23/33 50.0 55.5 ± 37.4 14/18 71.3 ± 32.1
Yolk sac 11/15 3.1 46.4 ± 39.1 9/15 3.8 43.5 ± 43.1 6/9 55.9 ± 37.1
AGM 4/15 2.7 32.7 ± 29.0 5/15 3.3 29.3 ± 30.0 2/2 71.0 ± 33.8
Fetal liver 12/25 80.0 36.6 ± 35.5 14/25 93.3 9.9 ± 22.0 8/14 17.8 ± 28.7
Blood 13/21 1.0 17.3 ± 20.0 15/20 1.3 14.8 ± 26.0 8/16 25.5 ± 36.3
Cord 1/4 0.25 45.7 1/4 0.25 66.8 1/1 82.9
Decidua 0/8 0 N/A 0/8 0 N/A N/A N/A
Total 129.9 152.0
a ER, engrafted recipients.
b Rec., Reconstitution.
c Only mice that survived over 5 months were included.
d sp, somite pairs.also in the placenta, and may therefore represent an-
other independent focus for de novo hematopoiesis, in
addition to the yolk sac and the embryo proper. This
hypothesis is supported by the expression of markers
that are associated with commitment of mesoderm to
hematopoietic fate such as brachyury, Flk1/VEGF-R2,
and SCL/tal1 (Chung et al., 2002) in the allantoises of
E7.5–E8.0 embryos (Drake and Fleming, 2000; Palis et
al., 1999) and runx1/AML1, a marker for HSC genesis,
in the distal tip of E8.5 allantois (North et al., 1999).
A possible erythropoietic role for murine allantois was
addressed in one study by culturing prefusion allanto-
ises from head-fold-stage embryos in vitro in explant
cultures and analyzing for the presence of benzidine-
positive, hemoglobinized red cells (Downs et al., 1998).
However, no signs of ongoing erythropoiesis in the ex-
plants were found.
Anatomical Origin of Placental HSCs: Placenta
as a Niche for HSCs that Are Generated Elsewhere
As the placenta is a highly vascular organ that is contin-
uously perfused with circulating blood cells, it was cru-
Developmental Cell
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bin the placenta and blood to assess the possibility that
placental HSCs would simply represent circulating f
iHSCs. Importantly, HSCs in the placenta appeared
earlier and in higher frequency than HSCs in circulating e
tblood, suggesting that placental HSCs represent a
unique stem cell population that is distinct from rareFigure 2. Multipotency and Self-Renewal
Ability of Placental HSCs
(A) Multilineage reconstitution ability of E11.5
placenta and AGM HSCs as assessed by the
presence of fetus-derived myeloid, B-lym-
phoid, and T-lymphoid cells in the recipients’
peripheral blood >5 months after transplan-
tation (representative animals are shown).
(B and C) Self-renewal ability of (B) E11.5 pla-
centa and (C) AGM HSCs upon serial trans-
plantation of BM from primary recipients.
Peripheral blood of secondary recipients
was analyzed 3 months after transplantation,
and reconstitution of individual secondary
recipients is shown as the competitive re-
population level, in linear scale. Comparable
symbols are used for each donor and se-
condary recipient.The placenta receives its blood supply from the dor-
Figure 3. Developmental Kinetics of Placental HSCs and Clonogenic Progenitors
(A) Number of total LT-RUs in fetal hematopoietic sites representing ability to repopulate peripheral blood >10–12 weeks after transplantation.
(B) Number of total in vitro clonogenic progenitors (CFU-Cs) in fetal hematopoietic sites. The graphs represent data from a minimum of three
individual transplantation experiments at each gestational age (see Table 1).irculating HSCs. However, as circulation has already
een established by the time that adult-type HSCs are
ound in the placenta, these data do not exclude seed-
ng of immature HSC precursors from other hematopoi-
tic sites for maturation into the placenta, or sequestra-
ion of rare circulating HSCs in placental HSC niches.
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371sal aorta via the umbilical artery, after which oxygen-
ated blood drains via the umbilical vein to the fetal liver
(Figure 5). In comparison, the vitelline vessels and the
yolk sac are not directly connected to the placental cir-
culation, but form another vascular circuit between the
dorsal aorta (upstream of the umbilical artery) and the
fetal liver. Interestingly, the AGM region does not harbor
large quantities of readily transplantable HSCs at any
time of development, in spite of the extensive potential
of AGM HSCs to expand in explant cultures (Kumara-
velu et al., 2002), suggesting that AGM HSCs are ex-
panded elsewhere in the conceptus. It has been sug-
gested that developing HSCs bud through the endothelial
wall of the dorsal aorta and umbilical and vitelline arter-
ies into the circulation (North et al., 1999), through
which they seed hematopoietic organs. As the placenta
is downstream of the dorsal aorta in fetal circulation,
AGM HSCs may circulate through the placenta prior to
colonizing the fetal liver. It is possible that the placenta
provides a temporary niche where nascent HSCs, or
their precursors, from the dorsal aorta and the umbilical
artery mature and expand.
The Placenta as a Prehepatic HSC Niche
that Supports HSCs without Promoting
Myeloerythroid Differentiation
The placenta and the fetal liver were the only two or-
gans that accumulated a large pool of readily trans-
plantable HSCs during midgestation. The c-kithiCD34+
surface phenotype of placental HSCs is comparable to
that of fetal liver and AGM HSCs (Figures 4B and 4C)Figure 4. Immunophenotype of Placenta and
Fetal Liver HSCs and Clonogenic Progen-
itors
(A and B) Surface phenotype analysis of
HSCs and clonogenic progenitors in (A)
E12.5 placenta and (B) fetal liver by flow
cytometry for expression of CD34 and c-kit.
The numbers on top of each quadrant indi-
cate the frequency of each cell population.
(C and D) Distribution of (C) HSCs and (D)
clonogenic progenitors between the four
isolated populations indicated in (A) and (B)
(n = 3 experiments). The numbers in (C) indi-
cate the number of engrafted mice/total re-
cipients transplanted with 0.05–0.3 ee from
each population. Error bars in (D) indicate
SD. R1, CD34−c-kit− ; R2, CD34+c-kit− ; R3,
CD34+c-kit+ ; R4 CD34−c-kit+.(Sanchez et al., 1996). A distinctive feature for CD34+
fetal HSCs is active cycling, which results in the expan-
sion of the HSC pool during development. In contrast,
HSCs in the adult BM are CD34+ and CD34−, the quies-
cent HSCs being in the CD34− fraction (Dao and Nolta,
2000; Ogawa et al., 2001; Zanjani et al., 1999). Analysis
of placental HSC and clonogenic progenitor frequencies
by phenotype and functional assays provided evidence
that the placental microenvironment supports pluripo-
tent HSCs without promoting their differentiation along
the myeloerythroid lineage. In contrast, the fetal liver, in
addition to harboring a similar c-kithiCD34+ population
enriched for HSCs as the placenta, was colonized with
a large number of progenitor cells that were committed
for definitive erythroid differentiation (i.e., CFU-Es and
CD71+ter119− proerythroblasts). These data implicate
inherent differences between fetal liver and placental
HSC/progenitor populations and hematopoietic micro-
environments, where the fetal liver, but not the pla-
centa, supports active myeloerythroid differentiation
during midgestation. These results are in accordance
with the data from Alvarez-Silva et al., who showed that
the hematopoietic developmental profile of placental
and fetal liver cells in methylcellulose was very dif-
ferent, as the placenta harbored multipotential, high-
proliferative potential progenitors, whereas the fetal
liver was rich in unilineage progenitors (Alvarez-Silva et
al., 2003).
The initially nonhematopoietic fetal liver rudiment is
colonized, first by hematopoietic progenitors and a few
days later by stem cells, when the vascular connections
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afirst task of fetal liver hematopoiesis is to produce de-
finitive red cells from yolk sac-derived progenitors. At
the same time, a pool of pluripotent HSCs accumulates P
Ain the placenta. It is possible that the initial maturation
and expansion of definitive HSCs occurs in a prehe- P
tpatic HSC niche in the placenta, separated from signals
that promote myeloerythroid differentiation. H
hThe microenvironmental cues that support HSCs in
the placenta are yet to be defined. Normal placental m
wdevelopment is critical for life, as shown by a large vari-
ety of mouse mutants that exhibit different degrees of l
splacental abnormalities that often underlie embryonic
lethality. These defects can arise from the allantoic, tro- t
Hphoblast, or maternal components of the placenta
(Rossant and Cross, 2001). Factors that support hema- e
ntopoiesis may be derived from the vasculogenic milieu
that drives the formation of the placenta labyrinth, as o
aHSC development and vasculogenesis share many
common regulators. Interestingly, different cell types
cderived from the trophoblast lineage (trophoblast giant
cells, spongiotrophoblasts, and syncytiotrophoblasts) b
iexpress a variety of growth factors and signaling mole-
cules such as PlGF, PDGF, IGF-2, and LIF, which have i
tbeen implicated to play a role in HSC biology in other
contexts (Constancia et al., 2002; Hattori et al., 2002; m
aKaminski et al., 2001; Leveen et al., 1994; Takahashi et
al., 2003; Zhang and Lodish, 2004). Furthermore, one of e
mthe unique features of the placenta is the intimate con-
tact with the maternal circulation that supplies the m
sgrowing embryo with oxygen and nutrients and is in-
volved in immune protection of the fetus. Understand- o
ting how the placenta supports HSC formation, matura-
tion, and/or expansion may ultimately give important v
aclues about how stemness in the hematopoietic system
is established and regulated, and may aid in developing r
Hbetter strategies for HSC expansion. Of note, one re-
cent study has reported the ability of a human pla- n
tcenta-derived mesenchymal progenitor cell line to sup-Figure 5. Revised Model of Fetal HSC Devel-
opment from Hematopoietic Commitment to
HSC Genesis and Expansion
(A) Allantois develops from the primitive
streak as a mesodermal extension in the exo-
coelomic cavity and fuses with the chorion.
The first signs of hematopoietic activity are
seen as yolk sac blood islands.
(B) Allantoic mesoderm has formed the um-
bilical vasculature and placenta labyrinth.
Colored circles in the large vessels, the yolk
sac, and the placenta illustrate putative sites
for de novo generation of progenitors and
HSCs. Hematopoietic seeding of the fetal
liver has been initiated via the vitelline and
umbilical veins from the yolk sac and the
placenta, respectively. The arrows indicate
the direction of circulation and possible routes
for seeding of HSCs and progenitors. Placenta
may serve as another site for HSC genesis and
as a niche for HSCs derived from the dorsal
aorta and the umbilical artery.
(C) The HSC pool in placenta expands during midgestation, suggesting maintenance/self-renewal of HSCs in the placenta microenvironment.
The decline of the placental HSC pool toward the end of gestation may reflect mobilization of placental HSCs to intraembryonic sites. dec,
decidua; epc, ectoplacental cone; ch, chorion; al, allantois; ys, yolk sac; e, embryo proper; lb, placenta labyrinth; da, dorsal aorta; ua, umbilical
artery; uv, umbilical vein; va, vitelline artery; vv, vitelline vein; fl, fetal liver.ort expansion of cord blood CD34+ cells (Zhang et
l., 2004).
lacental HSCs as a Source of Definitive,
dult-Type HSCs
lacental HSC activity declines toward the end of ges-
ation, possibly reflecting mobilization of placental
SCs to the fetal liver (Figure 5) and other developing
ematopoietic organs within the embryo, such as thy-
us, spleen, and bone marrow. Indeed, during the time
hen the placental HSC pool was diminishing, the fetal
iver HSC pool was continuously expanding and HSC
eeding had been initiated in the fetal spleen (Chris-
ensen et al., 2004). While mobilization of placental
SCs and colonization of intraembryonic hematopoi-
tic organs is an attractive hypothesis, these data do
ot exclude differentiation along the lymphoid pathway,
r cell death, as explanations for the decline of HSC
ctivity in the placenta.
Interestingly, no major influx of fetal HSCs into the
irculation was observed at any time. Rather, a low
asal level of long-term reconstituting HSCs was found
n circulating blood from E12.5 onward, slightly increas-
ng during the third trimester. These results are consis-
ent with previous studies and support the notion that
ost HSCs preferably reside in HSC niches, while only
small number circulate in the bloodstream (Abkowitz
t al., 2003; Christensen et al., 2004; McKinney-Free-
an and Goodell, 2004). Umbilical cord blood in hu-
ans and other mammals contains an accessible
ource for HSCs at term, although the major limitation
f the use of human cord blood stem cells in transplan-
ation is their low abundance, being insufficient to pro-
ide adequate hematopoietic recovery for adults (Cairo
nd Wagner, 1997). Whether cord blood cells represent
andomly circulating HSCs or a more concentrated
SC pool from the placenta and the umbilical cord is
ot fully defined, although studies comparing progeni-
or frequency in human cord blood and circulating
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373blood in newborn infants have implied that the compo-
sition of the two samples is similar (Zhang et al., 2002).
In order to put the magnitude of placental HSC activity
in perspective, it is worth noting that, in the mouse
embryo, the quantity of HSCs in the placenta during
midgestation (corresponding to 1–2 months of develop-
mental age in human embryos) far exceeds that present
at full term in the placenta, cord blood, and circulating
blood in toto. Whether the human placenta also func-
tions as a hematopoietic organ during development re-
mains to be studied.
These results show that the placenta provides a pre-
viously unappreciated source for pluripotent HSCs dur-
ing mouse development. While further studies are
needed to define the precise origin of placental HSCs
and the function of the placenta microenvironment as
an HSC-supportive niche, the unique kinetics and mag-
nitude of HSC activity in the placenta imply yet another




C57BL/6 (CD45.2) and C57BL/6.SJL (CD45.1) mice (Charles River
Laboratories or Taconic) were used to obtain CD45.1/CD45.2 F1
embryos, thus allowing the identification of maternal and fetal
hematopoietic cells. Mice were kept at the Animal Research facili-
ties at Children’s Hospital and Dana-Farber Cancer Institute, Bos-
ton, according to institutional guidelines. The day of copulation
plug was regarded as E0.5, and embryos between E9.5 and E11.5
were somite staged. The placenta, separated from the decidua,
and fetal hematopoietic tissues were dissected, and embryos were
exsanguinated for collection of fetal blood. At E9.5–E10.5, the cau-
dal half of the embryo comprising the pSP (para-aortic splanch-
nopleura)/AGM region and the fetal liver rudiment was analyzed in
one preparation. Care was taken to remove the umbilical and vitel-
line arteries from the placenta, the AGM, and the yolk sac. The
umbilical cord, decidua, and body remnants of the caudal half of
the embryo after dissection of AGM, and the rostral half of the
embryo, were analyzed in some experiments. Tissues were kept on
ice, washed in PBS, dissociated mechanically through a 16G nee-
dle, and treated with 0.12% collagenase type I (Sigma) in PBS with
10% FCS for 1.5 hr in 37°C, followed by passages through 18–25G
needles. Some experiments were performed in parallel with trypsin
treatment, which, in general, resulted in lower cell count and HSC/
progenitor yield (data not shown). Single cell suspensions were fil-
tered through 50 µm filters (Dako) and subjected to cell-counting
(Crystal violet, Sigma) and functional assays.
Methylcellulose Colony-Forming Assay
Clonogenic progenitors were assayed in 1% methylcellulose (Meth-
ocultTM, 3234, Stem Cell Technologies) supplemented with 10 ng/
ml IL3, 50 ng/ml SCF, 2 ng/ml IL6, 5 ng/ml Tpo, and 2 U/ml Epo.
Hematopoietic colonies were scored after 6–8 days of culture in
5% CO2 at 37°C. BFU-Es, CFU-GEMMs, CFU-GMs, and CFU-Ms
were counted in the total CFU-C count, whereas CFU-Es were
scored separately.
Competitive Repopulation Assay
Cells from the fetal hematopoietic organs were transplanted in lim-
iting dilutions (3–0.001 embryo equivalents, ee) together with 1 ×
105 unfractionated CD45.1 support/competitor BM cells into irradi-
ated CD45.2 adult female recipients via retro-orbital injection. Irra-
diation was split into two 550 rad doses, 3 hr apart. The recipient
mice were maintained in sterile cages with irradiated diet and anti-
biotic water (Baytril) for the first 4 weeks. Peripheral blood was
analyzed at 4–6 weeks, 10–12 weeks, and 5–12 months after trans-
plantation. Bone marrow, spleen, and thymus were analyzed at 10–
12 weeks or 5–8 months after transplantation. For serial transplant-ations, 1:10 and 1:100 of unfractionated BM cells from the primary
recipients was harvested at 10–12 weeks or 5–8 months and trans-
planted into irradiated secondary recipients together with competi-
tor cells, as described above.
Flow Cytometry
Hematopoietic reconstitution of peripheral blood, BM, spleen, and
thymus by fetal cells was analyzed by flow cytometric analysis
(FACS), by using FITC (fluorosceinisothiocyanate)-conjugated
CD45.2 and biotin-conjugated CD45.1 visualized by SAv (streptavi-
din)-APC (allophycocyanin). For lineage analyses, PE (phycoeryth-
rin)-conjugated antibodies against B220 (B cells), Gr1 and Mac1
(granulocytes and macrophages), and CD4 and CD8 (T cells) were
used. The immunophenotype of hematopoietic cells in fetal organs
was analyzed with PE-conjugated c-kit antibody and biotin-conju-
gated CD34 antibody, visualized by SAv-APC. All monoclonal anti-
bodies were purchased from BD Pharmingen.
Immunophenotyping of HSCs and Progenitors
The surface phenotype of placenta and fetal liver HSCs and clono-
genic progenitors was determined by FACS, followed by transplan-
tation and methylcellulose colony assay, respectively. Collagenase-
treated organs were stained for CD34 and c-kit as indicated above,
and cells in each organ were sorted into four subfractions (R1–R4,
Figures 4A and 4B). Equal embryo equivalents (0.2–0.3 ees for the
placenta and 0.05–0.2 ees for the fetal liver) of each subfraction
were transplanted into irradiated recipients, and reconstitution in
peripheral blood >12 weeks was assessed by flow cytometry. Simi-
larly, each subfraction was analyzed for clonogenic progenitor ac-
tivity.
Quantitation of HSC/RUs
The quantity of HSCs in each organ was assessed as reconstituting
units/embryo equivalent (RUs/ee), calculated by ([reconstituted re-
cipients]/[total recipients])/(transplanted dose). Peripheral blood re-
constitution over 10–12 weeks was regarded as positive HSC/RUs.
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